Mechanism and impact of allosteric AMPA receptor modulation by the AmpakineTM CX546
Introduction
Fast excitatory synaptic transmission in the central nervous system is mediated predominantly by Ī±-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) type glutamate receptors. The importance of this receptor family in brain function and potential downregulation of their functions in numerous diseases has triggered a strong interest to find drugs that interfere with its gating properties during synaptic transmission. Ubiquitous expression of AMPA receptors however have made it sofar difficult to identify modulators that act on specific function of the nervous system such as memory, cognition and other neurological states. Heteromeric assembly of the AMPA receptor subunits GluR1-4 form ionotropic ion channels that can transduce the presynaptic signal into a surprisingly variable postsynaptic response. The subunit composition varies with particular brain region, with the cell type and during development. Further posttranslational modification of the AMPA receptor gene alters channel gating and permeability in a distinct fashion, mainly influencing receptor deactivation and desensitization. Whilst their individual contributions are debated, these two parameters are thought to be the crucial parameters that shape the synaptic response.
Recent structural and functional data provide detailed insights into both the intricate molecular mechanisms underlying activation, deactivation and desensitization of AMPA receptors and how the gating properties are modulated by drugs (Armstrong and Gouaux, 2000, Partin, 2001, Stern-Bach et al., 1998). A number of allosteric modulators that affect the process of desensitization and deactivation have been characterized in detail. These include the benzothiadiazides such as cyclothiazide, diazoxide and IDRA 21 (Bertolino et al., 1993, Patneau et al., 1993, Yamada and Rothman, 1992, Yamada and Tang, 1993), the pyrrolidinone analogs aniracetam, piracetam (Gouliaev and Senning, 1994, Isaacson et al., 1991, Partin et al., 1996, Tang et al., 1991), and a heterologous group of substances named ampakines, whose properties have been characterized to modify AMPA receptor function. Ampakines include modulators such as BCP, CX516, CX546 (Arai et al., 1996c, Holst et al., 1998, Lauterborn et al., 2000, Lynch, 1998). Most modulators are relatively specific for AMPA-type glutamate receptors which also, in part, affect splice variant (flip/flop) differentially (Partin et al., 1995, Partin et al., 1996).
Among benzothiadiazides, cyclothiazide is one of the most potent modulators that is best understood in terms of its mechanism of action (Partin, 2001, Partin et al., 1996, Partin et al., 1994, Partin et al., 1993, Yamada and Tang, 1993). IDRA 21, being less potent than cyclothiazide but more potent than diazoxide and aniracetam (Bertolino et al., 1993), has gained strong interest because of its non-neurotoxic effects in primary cultures, potency in abating pharmacologically induced cognitive impairments in patas monkeys (Impagnatiello et al., 1997, Thompson et al., 1995), cognition enhancement in rats (Zivkovic et al., 1995) and promoting the induction of long term potentiation (LTP) (Arai et al., 1996a). On the negative side, recent reports (Yamada et al., 1998) show that IDRA 21 worsens neuronal ischemic injury due to excessive AMPA receptor activation.
Ampakines are molecular entities that have shown their importance as positive modulators in enhancing memory of rodents and humans (Granger et al., 1996, Ingvar et al., 1997, Larson et al., 1995). The potential significance of ampakines in their therapeutic effectiveness arises due to their ability to freely cross the bloodābrain barrier (Staubli et al., 1994b), promote LTP induction in vivo (Lynch, 1998), improve short term memory in radial maze (Staubli et al., 1994a), facilitate olfactory learning (Larson et al., 1995), and effectively boost transmission in complex neuronal networks (Sirvio et al., 1996). Ampakines like BDP20 (Arai et al., 1996b), CX614 (Arai et al., 2000) and BDP12 (Arai et al., 1996c) are apparently without direct agonistic or antagonistic properties and do not affect the membrane potential or inhibitory transmission to a detectable extent (Arai et al., 1996c). They are thought to act by modulating the kinetics of desensitization and deactivation (channel closing and transmitter dissociation), resulting in a modified shape of excitatory synaptic responses (Arai et al., 1996b, Arai and Lynch, 1998). Binding tests on AMPA subunits have shown that some ampakines like CX614 or BDP-37 apparently do not have major preferences for flip/flop splice variants (Arai et al., 2000, Hennegriff et al., 1997).
In the current investigation, we have examined the pharmacological action of structurally distinct modulators IDRA 21 (a benzothiadiazine derivative) and the ampakines CX516 and CX546 (benzoylpiperidine derivatives) on flip version of wild-type GluR1/2, the nondesensitizing GluR1L497Y, native receptors and on synaptic transmission. Most analysis is concerned with the action of CX546, a more potent analog than CX516. We compared the less characterized basic kinetic properties of their modulatory action to gain insight into the molecular mechanism during channel gating and desensitization process. Our results on recombinant and native receptors show a striking difference in the degree of modulation based on the subunit composition as well as in their apparent mode of action. All drugs tested modulated excitatory synaptic currents by moderately enhancing the peak amplitude and slowing down EPSCs, although with differing efficacy.
Section snippets
Plasmids and mutagenesis
cDNAs encoding the alternatively spliced flip version of wild type GluR1Q and GluR2Q (Sommer et al., 1990) were used for all the experiments. Point mutations were introduced as described (Stern-Bach et al., 1998). All receptors were subcloned into pRK5 vectors (InVitrogen). Amino acid numbering starts from the first methionine of the open reading frame.
Cell culture and transfections
Cells from the human embryonic kidney cell line HEK293 (ATCC, USA) were cultured in RPMI 1640 (Gibco BRL) supplemented with 10% fetal calf serum
Results
We first describe the basic modulatory action of the benzoylpiperidines CX546 and CX516 and the benzothiadiazides IDRA 21 (Fig. 1) on a defined AMPA receptor population. We used flip splice variants of wild-type GluR1 and also the unedited large conducting GluR2Q receptor to probe for the potential differences between subunits. The subunits were transiently transfected in HEK293 cells (Chen and Okayama, 1988) and outside-out patches were exposed to control and agonist solution in the absence or
Discussion
The goal of this study was to examine the mechanism of two exemplary AMPA receptor modulators of a functionally defined class, the ampakines CX546 and CX516 (benzoylpiperidine derivatives), and compare these with a well studied class of benzothiadiazide modulators such as cyclothiazide and IDRA 21. On recombinant or native AMPA receptors, CX546 reduced the degree of desensitization more potently than CX516 or IDRA 21, but not as efficiently as cyclothiazide. We noted larger absolute
Acknowledgments
The authors thank Cortex Pharmaceuticals Inc. for providing the ampakines CX516 and CX546 used in this study, Dr. Peter H. Seeburg and Dr. Yael Stern-Bach for cDNA clones and Ina Herfort for technical assistance.
References (58)
- et al.
Effects of a centrally active benzoylpyrrolidine drug on AMPA receptor kinetics
Neuroscience
(1996) - et al.
The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization
Brain Research
(1998) - et al.
Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core [In Process Citation]
Neuron
(2000) - et al.
Prolonged presence of glutamate during excitatory synaptic transmission to cerebellar Purkinje cells
Neuron
(1994) - et al.
LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons
Neuropharmacology
(2001) - et al.
Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor
Neuron
(1991) - et al.
Asynchronous release of synaptic vesicles determines the time course of the AMPA receptor-mediated EPSC
Neuron
(1995) - et al.
Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro
Neuropharmacology
(2001) - et al.
Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS
Neuron
(1995) - et al.
Piracetam and other structurally related nootropics
Brain Research Reviews
(1994)
Enhancement by an AmpakineTM of memory encoding in humans
Experimental Neurology
Memory and the brain: unexpected chemistries and a new pharmacology
Neurobiology of Learning and Memory
Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans
Experimental Neurology
Structural determinants of allosteric regulation in alternatively spliced AMPA receptors
Neuron
Selective modulation of desensitization at AMPA versus kainate receptors by cyclothiazide and concanavalin A
Neuron
The mechanism of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor desensitization after removal of glutamate
Biophyics Journal
Complexins regulate a late step in Ca2+-dependent neurotransmitter release
Cell
Effects of pharmacologically facilitating glutamatergic transmission in the trisynaptic intrahippocampal circuit
Neuroscience
A point mutation in the glutamate binding site blocks desensitization of AMPA receptors
Neuron
Enantiomeric resolution with a new chiral stationary phase of 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide, a cognition-enhancing benzothiadiazine derivative
Journal of Pharmacological Science
Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease?
Neurobiological Disease
Effect of the AMPA receptor modulator IDRA 21 on LTP in hippocampal slices
Neuroreport
Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus
Journal of Pharmacology and Experimental Therapy
Effects of the potent AmpakineTM CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466
Molecular Pharmacology
Structure of a glutamate-receptor ligand-binding core in complex with kainate
Nature
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator
Journal of Pharmacology and Experimental Therapy
Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture
Proceedings of the National Academy of Sciences of the USA
Modulation of AMPA/kainate receptors by analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus
Receptors Channels
Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA
Biotechniques
Cited by (74)
Rh(III)-Catalyzed CāH Annulation of 3-Aryl-2H-benzo[e][1,2,4]thiadiazine-1,1-dioxides with Vinylene Carbonates
2024, European Journal of Organic ChemistryIron-catalyzed synthesis of N-heterocycles via intermolecular and intramolecular cyclization reactions: A review
2022, Arabian Journal of ChemistryEasy preparation of novel 3,3-dimethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide: Molecular structure, Hirshfeld surface, NCI analyses and molecular docking on AMPA receptors
2021, Journal of Molecular StructureCitation Excerpt :Studies have proven that enhancement of Ī±-amino-3āhydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) signals by compounds known as AMPAR potentiators could be beneficial in the management of these neurological disorders pathologies [1-3]. Indeed, various research groups have become interested in AMPA receptors (AMPARs) and shown that upregulation of these receptors could produce cognition enhancement [4]. The modulatory activity of AMPA positive allosteric modulators (AMPApams) derive from the fact that when binding with the ligand-binding domain (LBD), positive allosteric modulators stabilize the receptor in its open state and therefore slowing the deactivation and/or the desensitization processes, or induce conformational modification leading to the closure of the channel [5-8].